T. Feys MBA, MSc

Highlights in chronic myeloid leukemia

SUMMARY

Treatment discontinuation has become a central issue in studies with BCR-ABL tyrosine kinase inhibitors (TKIs) in chronic myeloid leukemia (CML). The oral session on clinical trials in CML featured two studies on treatment discontinuation: one assessing initial reduction before complete TKI withdrawal and a second study evaluating the impact of minimal residual disease (MRD) on the outcome of imatinib discontinuation. In addition to this, a study was presented with long-term data on 400mg imatinib as first-line treatment for CML together with a study assessing frontline bosutinib. Finally, a last abstract in this session evaluated the second-generation BCR-ABL TKI dasatinib in children and adolescents with CML.

(BELG J HEMATOL 2017;8(4):151–4)

Highlights in indolent non-hodgkin lymphoma and diffuse large B-cell lymphoma

SUMMARY

As usual, June was a very busy month for lymphoma specialists, with back to back, international meetings. This report will summarize some key data related to non-hodgkin lymphoma, presented during the 2017 International Conference on Malignant Lymphoma (ICML; Lugano June 14–17) and the 2017 annual meeting of the European Hematology Association (EHA; Madrid June 22–25). We would like to acknowledge Prof Ann Janssens (University Hospital Leuven) for her help in selecting the abstracts presented here.

(BELG J HEMATOL 2017;8(4):158–64)

Highlights in thrombosis and inherited platelet disorders

(BELG J HEMATOL 2017;8(4):166–7)

New haematology reimbursements in Belgium

OVERVIEW OF BELGIAN REIMBURSEMENT NEWS

(BELG J HEMATOL 2017;8(3):125–6)

Biosimilars in the Belgian health care plan

(BELG J HEMATOL 2017;8(2):87–8)

New haematology reimbursements in Belgium

OVERVIEW OF BELGIAN REIMBURSEMENT NEWS

(BELG J HEMATOL 2017;8(2):89)

Highlights in haematological cancer from the 2016 annual meeting of the American Society of Clinical Oncology (ASCO)

Summary

From June 3^rd till June 6^th, Chicago again formed the background for the biggest cancer congress in the world. Notwithstanding the fact that solid tumours remain the main focus of the annual meeting of the American Society of Clinical Oncology (ASCO), the meeting program also included some interesting lectures on haematological malignancies. The aim of this report is not to discuss all these studies, but will address some of the key presentations on haematological cancer from ASCO 2016. For a more complete overview we would like to refer to the congress website, where all abstracts and a plethora of webcasts can be found.

(BELG J HEMATOL 2016;7(5):203–6)